New CAR-T therapy targets tough childhood leukemia
NCT ID NCT07338357
First seen Jan 16, 2026 · Last updated Apr 29, 2026 · Updated 14 times
Summary
This early-phase study tests a new treatment called CLL-1 CAR-T for children aged 3 to 18 with acute myeloid leukemia (AML) that has come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified to recognize and attack leukemia cells. The main goal is to check safety, and researchers will also see if it helps shrink the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML - ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.